Your browser doesn't support javascript.
loading
The Impact of potential 'confounders' on the diagnostic sensitivity of circulating free DNA in management of FIT+ patients: a pilot study.
Scimia, Mauro; Pepe, Francesco; Russo, Gianluca; Palumbo, Lucia; Malapelle, Umberto; Chuang, Rachel; Scimia, Simone; Sha, Michael; Tanaka, Hiromi; Shen, Shuo; Chen, David; Troncone, Giancarlo; Bianco, Maria Antonia.
Afiliación
  • Scimia M; DiaCarta Inc, Richmond, Virginia, USA.
  • Pepe F; Public Health, University of Naples Federico II, Naples, Italy.
  • Russo G; Public Health, University of Naples Federico II, Naples, Italy.
  • Palumbo L; Public Health, University of Naples Federico II, Naples, Italy.
  • Malapelle U; Public Health, University of Naples Federico II, Naples, Italy umberto.malapelle@unina.it.
  • Chuang R; DiaCarta Inc, Richmond, Virginia, USA.
  • Scimia S; DiaCarta Inc, Richmond, Virginia, USA.
  • Sha M; DiaCarta Inc, Richmond, Virginia, USA.
  • Tanaka H; DiaCarta Inc, Richmond, Virginia, USA.
  • Shen S; DiaCarta Inc, Richmond, Virginia, USA.
  • Chen D; DiaCarta Inc, Richmond, Virginia, USA.
  • Troncone G; Public Health, University of Naples Federico II, Naples, Italy.
  • Bianco MA; Gastroenterology and Digestive Endoscopy Unit, ASL NAPOLI 3 SUD, Nola, Italy.
J Clin Pathol ; 77(8): 557-560, 2024 Jul 18.
Article en En | MEDLINE | ID: mdl-38649261
ABSTRACT
Cell-free DNA (cfDNA) has long been established as a useful diagnostic and prognostic tool in a variety of clinical settings, ranging from infectious to cardiovascular and neoplastic diseases. However, non-neoplastic diseases can act as confounders impacting on the amount of cfDNA shed in bloodstream and on technical feasibility of tumour derived free circulating nucleic acids selecting patients with cancer. Here, we investigated the potential impact of other pathological processes in the clinical stratification of 637 FIT+ patients. A single and multiple logistic regression yielded similar results. Crude sensitivity was 75.9% versus adjusted sensitivity of 74.1%, relative risk 0.9761 (0.8516 to 1.1188), risk difference 0.0181 (-0.0835 to 0.1199) and OR 0.9079 (0.5264 to 1.5658). Potential confounding effect from other source of cfDNA plays a pivotal role in the clinical stratification of FIT+ patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Ácidos Nucleicos Libres de Células Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Pathol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Ácidos Nucleicos Libres de Células Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Pathol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido